AstraZeneca Caps Out-of-Pocket Inhaler Costs at $35 Per Month
Drug Topics
MARCH 18, 2024
AstraZeneca is the second pharmaceutical company to cap out-of-pocket costs for eligible patients.
Mon.Mar 18, 2024
360 
Ex-Novartis exec sets out to create ‘Apple of AI’
PharmaVoice
MARCH 18, 2024
Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Efficacy of Tapinarof Cream 1% Demonstrated in Atopic Dermatitis in Skin of Color
Drug Topics
MARCH 18, 2024
A lack of diversity in clinical trials has hampered health care providers from understanding the nuances of diseases across specific patient populations.
STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’
STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A Pharmacy Consult with a Patient living with Bipolar I Disorder, Previously Using Oral Antipsychotics and Considering LAIs
Drug Topics
MARCH 18, 2024
This video was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. in collaboration with Lundbeck LLC.
FDA Advisory Committee Votes in Favor of Ide-Cel for Adult Patients With Multiple Myeloma
Pharmacy Times
MARCH 18, 2024
The decision to vote in favor of idecabtagene vicleucel comes after positive phase 3 trial results demonstrating its efficacy compared with standard regimens.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
STAT+: FDA approves first gene therapy for a fatal neuron disease in children
STAT
MARCH 18, 2024
The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons. The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today.
A Pharmacy Consult with Patient with Bipolar 1 Considering Gluteal Injection of LAI
Drug Topics
MARCH 18, 2024
This video was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. in collaboration with Lundbeck LLC.
Bacterial Load in Spinal Fluid Could Predict Pneumococcal Meningitis Outcomes
Pharmacy Times
MARCH 18, 2024
High bacterial load in cerebrospinal fluid was associated with unfavorable outcomes and death for adults with pneumococcal meningitis.
STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?
STAT
MARCH 18, 2024
I was wrong about Geron. For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved , I said. On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NCPA, Biosimilar Forum Voice Support for PBM Reform Bill
Pharmacy Times
MARCH 18, 2024
Senators Ron Wyden and Mike Crapo reaffirm their support on 2 health care bills that passed the United States Senate Committee on Finance in 2023.
5 Big Pharma CEOs who saw major pay bumps in 2023
PharmaVoice
MARCH 18, 2024
Pharma’s recent wins have led to pay windfalls for several company leaders.
Topical Minoxidil Improves Hair Growth in 87% of Pediatric Patients With Chemotherapy-Induced Alopecia
Pharmacy Times
MARCH 18, 2024
The FDA-approved topical and oral agent is currently indicated for adult patients with patterned alopecia.
STAT+: As AI marches into medicine, investors eye security, privacy startups
STAT
MARCH 18, 2024
Investors are starting to back startups that offer privacy and security services to bolster health AI products already on the market while they wait for crucial safety and privacy regulations to take shape. Though health leaders are racing to deploy generative AI products that can automatically transcribe doctor-patient conversations during medical appointments or churn through massive repositories of scientific research, they’re still flummoxed about how to measure their quality.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
#FierceMadness: Grab a bracket and vote for the most overused buzzword in healthcare!
Fierce Healthcare
MARCH 18, 2024
The NCAA basketball tournament gets underway today, and the Fierce Healthcare team is gearing up yet again for our annual #FierceMadness competition. | The NCAA basketball tournament gets underway today, and the Fierce Healthcare team is gearing up yet again for our annual #FierceMadness competition.
Study Results Show Evolving DNA Methylation Can Help Understanding of Hematologic Diseases
Pharmacy Times
MARCH 18, 2024
The authors note that understanding the DNA methylation profile in leukemia can help predict whether or not a patient will respond to treatment.
Akums introduces Hydroxyurea oral suspension for sickle cell disease
Pharmaceutical Technology
MARCH 18, 2024
Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, a room temperature-stable drug for treating sickle cell disease.
Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
Pharmacy Times
MARCH 18, 2024
Michael Singel, PharmD, discusses the role of pharmacists in the operationalization of bispecifics to treat multiple myeloma, including the creation of treatment plans and standard of care order sets.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Patient-centricity and HCP engagement: 7 Challenges in pharma and life sciences outreach
pharmaphorum
MARCH 18, 2024
Discover the top 7 challenges faced by pharmaceutical and life sciences companies in achieving patient-centricity and engaging healthcare professionals (HCPs). Explore strategies to overcome these obstacles for successful outreach efforts.
Contineum Therapeutics files for IPO
STAT
MARCH 18, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we ponder the vast open spaces of Boston’s unused life sciences labs, see a new biopharma IPO in the works, and expect a label expansion for some CAR-T blood cancer therapies.
CAR-Ts set to move earlier in multiple myeloma therapy
pharmaphorum
MARCH 18, 2024
FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broader patient population.
Clover Health, Quarter Health team up against serious mental illness
Fierce Healthcare
MARCH 18, 2024
High-risk Clover Health members can now take advantage of Quartet Health's behavioral health offerings to help individuals suffering from serious mental illness. | Quartet Health is partnering with Clover Health to help the insurtech's most complex patients suffering from serious mental illness.
Agreement reached on EU health data framework
pharmaphorum
MARCH 18, 2024
Agreement has been reached in the EU on a European Health Data Space (EHDS), which will make it easier to exchange and access electronic health data.
STAT+: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more
STAT
MARCH 18, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and inspiring, because that oh-so familiar routine of online meetings, phone calls, and deadlines has returned. You knew this would happen, yes? After all, the world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup of stimulation.
NHS will expand use of waiting list-busting AI after pilot
pharmaphorum
MARCH 18, 2024
AI software designed to tackle missed appointments and reduce waiting lists will see its use by NHS England ramp up after a successful pilot deployment.
Promoting Nutrition Education and Sustainable Eating Practices for National Nutrition Month
Pharmacy Times
MARCH 18, 2024
Laura Brown, MS, RDN, LDN, discusses the importance of National Nutrition Month, collaborating with pharmacists, promoting sustainable eating habits, and overcoming common nutrition misconceptions
OS data set up wider Jemperli use in endometrial cancer
pharmaphorum
MARCH 18, 2024
GSK's PD-1 inhibitor Jemperli improves overall survival when used first-line in an all-comer endometrial cancer trial
Mould study highlights safer far-UVC light cleaning alternative
European Pharmaceutical Review
MARCH 18, 2024
A study has determined that intermittent low-intensity far-UVC light can inhibit mould growth below the threshold limit value of 23 mJ/cm 2. At 222nm, far-UVC light was shown to prevent development of common mould-producing fungi , specifically Penicillium candidum. The on-off duty cycle pattern of the far-UVC light used in the study is “consistent with its use in real-world settings”, the corresponding paper stated.
Reading the Tea Leaves on Recent Surge in Pharma Dealmaking
Pharmaceutical Commerce
MARCH 18, 2024
In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.
After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US
Fierce Pharma
MARCH 18, 2024
Kyowa Kirin’s bet on Orchard Therapeutics has paid off, furnishing the Japanese drugmaker with a newly approved gene therapy in the U.S. | The FDA on Monday gave a thumbs up to Lenmeldy as the first gene therapy in the U.S. for kids with certain types of metachromatic leukodystrophy (MLD).
BMS completes $14bn takeover of Karuna
pharmaphorum
MARCH 18, 2024
Bristol-Myers Squibb gets its $14bn takeover of Karuna Therapeutics over the finish line, taking control of schizophrenia candidate KarXT ahead of an FDA decision in September
Pfizer set to collect roughly $2.6B in selloff of Haleon shares, reducing stake from 32% to 24%
Fierce Pharma
MARCH 18, 2024
Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is | Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is prepared to do the same with a larger selloff, according to the consumer healthcare company. Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering.
MS and fibrosis drug developer Contineum files $150m IPO
pharmaphorum
MARCH 18, 2024
Contineum Therapeutics joins IPO queue, seeking $150m for its pulmonary fibrosis and multiple sclerosis candidates
Let's personalize your content